Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931409 | 0.93 | GGT1 (0.47) | GGT1FOLH1RIMKLANAALAD2MEN1 | |
| SCHEMBL29372593 | 0.85 | GGT1 (0.42) | GGT1TGFBR1NOD1 | |
| SCHEMBL20836757 | 0.85 | GGT1 (0.42) | GGT1FOLH1RIMKLANAALAD2MEN1 | |
| SCHEMBL2163628 | 0.85 | GGT1 (0.65) | GGT1FOLH1TGFBR1ACENOD1 | |
| SCHEMBL2450582 | 0.85 | FOLH1 (0.55) | GGT1FOLH1RIMKLANAALAD2 | |
| SCHEMBL7264181 | 0.85 | CHRM1 (0.43) | GGT1FOLH1TGFBR1NOD1 | |
| SCHEMBL313184 | 0.85 | GGT1 (0.42) | GGT1FOLH1RIMKLANAALAD2MEN1 | |
| SCHEMBL4655464 | 0.85 | FOLH1 (0.55) | GGT1FOLH1RIMKLANAALAD2 | |
| SCHEMBL29058786 | 0.85 | GGT1 (0.42) | GGT1FOLH1RIMKLANAALAD2MEN1 | |
| SCHEMBL6552817 | 0.85 | GGT1 (0.42) | GGT1TGFBR1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. | 2022-12-29 | — | — | US | claimed |
| WO-2022204327-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4041268-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114786697-A | Diterpenoids acting on Protein Kinase C (PKC) | K-GEN股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4351581-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Victoria Link Limited (NZ) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| US-7883713-B2 | Suspension, ointment, solution, spray, lotion, gel, cream, powder, powder spray, paste, emulsion, foam or stick; for treatment of herpes infections in humans | AICURIS GMBH & CO. KG (DE) | 2011-02-08 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | GGT1 1685/4885FOLH1 2243/4885RIMKLA 1388/4885 |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | AADAC, AADAT, AASDHPPT | GGT1 1180/4885FOLH1 551/4885RIMKLA 408/4885 |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | EBNA1BP2, RPL35, RPL7 | GGT1 811/4885FOLH1 2475/4885RIMKLA 1657/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | GGT1 929/4885FOLH1 189/4885RIMKLA 651/4885 |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCH, PRKCB | GGT1 652/4885FOLH1 2409/4885RIMKLA 3598/4885 |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | PLG, AADAC, DNPEP | GGT1 756/4885FOLH1 285/4885RIMKLA 534/4885 |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCB, PRKCI | GGT1 887/4885FOLH1 4247/4885RIMKLA 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.